Patents by Inventor Chih-jen Wei
Chih-jen Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11904009Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.Type: GrantFiled: October 1, 2020Date of Patent: February 20, 2024Assignee: SANOFIInventors: Gary J. Nabel, Chih-Jen Wei, Kurt Swanson
-
Publication number: 20240050518Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.Type: ApplicationFiled: June 15, 2023Publication date: February 15, 2024Applicant: SANOFIInventors: Gary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou, Stefan Koester
-
Publication number: 20230277619Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.Type: ApplicationFiled: December 19, 2022Publication date: September 7, 2023Applicant: SANOFIInventors: Gary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou, Stefan Koester
-
Patent number: 11617780Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.Type: GrantFiled: October 1, 2020Date of Patent: April 4, 2023Assignee: SANOFIInventors: Gary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou, Stefan Koester
-
Publication number: 20220119457Abstract: This disclosure relates to antigenic multimeric respiratory syncytial virus (RSV) G polypeptides for use in eliciting an immune response to RSV.Type: ApplicationFiled: September 29, 2021Publication date: April 21, 2022Applicant: SanofiInventors: Kurt Swanson, Chih-Jen Wei, Gary J. Nabel
-
Publication number: 20210113681Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.Type: ApplicationFiled: October 1, 2020Publication date: April 22, 2021Applicant: SANOFIInventors: Gary J. Nabel, Chih-Jen Wei, Kurt Swanson
-
Publication number: 20210017238Abstract: This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SanofiInventors: Gary J. Nabel, Chih-Jen Wei, Heather Kamp, Ronnie Wei, Kurt Swanson
-
Publication number: 20210015896Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SanofiInventors: Gary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou, Stefan Koester
-
Publication number: 20210017237Abstract: This disclosure relates to antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV. Also disclosed are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SanofiInventors: Gary J. Nabel, Chih-Jen Wei, Kurt Swanson, Pradeep Dhal, Ram Dharanipragada, Magnus Besev
-
Patent number: 10137190Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: GrantFiled: August 23, 2016Date of Patent: November 27, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Masaru Kanekiyo, Chih-Jen Wei, Patrick M. McTamney, Hadi M. Yassine, Jeffrey C. Boyington
-
Publication number: 20170189518Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: ApplicationFiled: August 23, 2016Publication date: July 6, 2017Inventors: Gary J. NABEL, Masaru KANEKIYO, Chih-Jen WEI, Patrick M. MCTAMNEY, Hadi M. YASSINE, Jeffrey C. BOYINGTON
-
Patent number: 9441019Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: GrantFiled: September 24, 2012Date of Patent: September 13, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Masaro Kanekiyo, Chih-Jen Wei, Patrick M. McTamney, Hadi M. Yassine, Jeffrey C. Boyington
-
Publication number: 20140302079Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: ApplicationFiled: September 24, 2012Publication date: October 9, 2014Inventors: Gary J. Nabel, Masaro Kanekiyo, Chih-Jen Wei, Patrick M. Mctamney, Hadi M. Yassine, Jeffrey C. Boyington
-
Publication number: 20140072958Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: ApplicationFiled: March 1, 2013Publication date: March 13, 2014Inventors: Gary J. NABEL, Masaru KANEKIYO, Chih-Jen WEI, Patrick M. MCTAMNEY, Hadi M. YASSINE, Jeffrey C. BOYINGTON
-
Publication number: 20120219584Abstract: Immunogens and compositions are provided that encode a protein comprising an influenza A subtype H1 hemagglutinin glycan-shielded receptor binding domain A (RBD A) region and at least one influenza A subtype H1 hemagglutinin antigenic site wherein the antigenic site is not within the RBD-A region. Also provided are immunogens and compositions that encode an immunogenic protein comprising at least one epitope of the RBD-A region of a pandemic influenza A subtype H1 hemagglutinin antigen. Also provided are such proteins, nucleic acids that encode such proteins, and antibodies against such proteins. Also provided are methods to use such immunogens and compositions to elicit a neutralizing antibody immune response against influenza A subtype H1 virus.Type: ApplicationFiled: October 5, 2010Publication date: August 30, 2012Applicant: THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTHInventors: Gary J. Nabel, Chih-Jen Wei, Zhi-Yong Yang, Jeffrey Boyington
-
Publication number: 20110177122Abstract: The present invention relates to a combination of a priming composition and a boosting composition to prime and boost an immune response in a subject whereby the immune response resulting from administration of the priming composition to the subject is capable of being boosted. The priming composition comprises a DNA plasmid that comprises a nucleic acid molecule encoding an influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof. The boosting composition comprises an influenza vaccine. The present invention also relates to a method to use such a combination to vaccinate a subject and to enhance an immune response to an influenza vaccine administered alone. Such a combination can elicit an immune response not only against at least one influenza virus strain from which the priming composition or boosting composition is derived but also to at least one heterologous influenza virus strain.Type: ApplicationFiled: September 25, 2009Publication date: July 21, 2011Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Gary J. Nabel, Chih-jen Wei, Zhi-Yong Yang
-
Publication number: 20110171260Abstract: The present invention relates to an influenza immunogen that includes one or more DNA constructs encoding at least two divergent influenza HAs, wherein each of such one or more DNA constructs encodes one or more of the at least two divergent influenza HAs. Such an immunogen, when administered to a subject, induces an immune response to a plurality of strains of influenza virus, wherein at least one strain of the plurality of strains does not encode any of the divergent influenza HAs encoded by the immunogen. The divergent influenza HAs can be swine influenza HAs or equine influenza HAs, such as influenza H1 HAs or influenza H3 HAs. The invention also relates to a method to use such an immunogen to induce such an immune response as well as to DNA constructs comprising such divergent influenza HAs. Such an immunogen can provide a heterologous as well as a homologous immune response. Such an immunogen can be used to induce an immune response against evolving influenza virus.Type: ApplicationFiled: July 16, 2010Publication date: July 14, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER.Inventors: SRINIVAS RAO, GARY J. NABEL, ZHI-YONG YANG, CHIH-JEN WEI, WING-PUI KONG
-
Publication number: 20100074916Abstract: H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines.Type: ApplicationFiled: October 10, 2007Publication date: March 25, 2010Applicant: Government of the United States of America, as represented by the Secretary, Dept. of Health andInventors: Gary J. Nabel, Zhi-yong Yang, Chih-jen Wei, Wing-pui Kong, Lan Wu